In fact, a systematic review aiming to identify factors associated with adherence to insulin therapy in type 1 and type 2 diabetes showed that adherence is generally poor and suggested that more flexible regimen may improve it as well as facilitating insulin deliver by switching to a pen device [14]
Windelov JA, Wewer Albrechtsen NJ, Kuhre RE et al (2017) Why is it so difficult to measure glucagon-like peptide-1 in a mouse
Die Krankenkassen bernehmen die Kosten fr GLP-1-Agonisten bisher nur bei der Behandlung von Diabetes mellitus Typ 2, nicht bei Adipositas
And expect some degree of increased bloating for 24-48 hours afterward
Both are once-weekly subcutaneous injections administered in the abdomen, thigh, or upper arm
Yes, but long-term use should be monitored by a healthcare professional to assess safety and effectiveness